Clinical Trials
42 trialsAMYLOCARP
Ramsay Générale de Santé
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital
MGUS-PET
University of Zurich
CArdiag
Lantheus Biosciences Ltd.
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
Stanford University
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
National Cancer Institute (NCI)
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Kedrion S.p.A.
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Attralus, Inc.
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
SWOG Cancer Research Network
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
Institute of Hematology & Blood Diseases Hospital, China
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd.
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
European Myeloma Network B.V.
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
ETCABIO
University Hospital, Angers
ALACRITY
Alexion Pharmaceuticals, Inc.
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
ALANIS
GlaxoSmithKline
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
BMT
Massachusetts General Hospital
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
M.D. Anderson Cancer Center
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Emory University
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Teclistamab-Daratumumab in AL Amyloidosis
Columbia University
MICA
Brigham and Women's Hospital
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Peking University First Hospital
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
SWOG Cancer Research Network
EMN27
European Myeloma Network B.V.
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Anhui Provincial Hospital
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Peking Union Medical College Hospital
NEXICART-2
Nexcella Inc.
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
Nanjing IASO Biotechnology Co., Ltd.
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University